Clearcut Medical Ltd.

clrcut.com

Clear-Cut Medical aims to redefine cancer surgery and pathology. A successful surgery removes all cancerous tissue and achieves optimal, functional as well as cosmetic outcomes by sparing healthy tissue. Depending on cancer type, between 5% and 35% of surgeries fail to achieve these goals in the first attempt, causing expensive and difficult re-operations as well as higher follow-up treatment costs. Clear-Cut’s solution is to provide the operating surgeon with real-time feedback about the surgical margin status, allowing both complete cancer removal and conservation of healthy tissue during the surgical procedure. Current approaches are expensive, unreliable and/or not timely—like the gold standard histopathology, which delivers critical information only several days after the surgery. To this end, the company has developed the ClearSight surgical MRI, which combines small footprint, total mobility for intra-operative use and zero complexity—the “microwave oven of MRI.” The device has shown industry-leading accuracy in comparison to histopathology in two multi-center trials and is CE marked. The company is initially focusing on breast conserving surgery, with a TAM of $1.2 billion in the US and Europe. Other cancers will be added in time, with lung cancer being addressed in 2018. The business model is based on a high margin, single-use tissue container rather than the classical capital equipment model.